Borrow "two districts" construction!Changping will create "Life Valley Dart Innovation Complex"

On September 2nd, the reporter learned from the "two districts" construction results conference of the Changping District of the Changping District in 2022 that Changping will create a "Life Valley Dart Innovation Complex" of about 75,000 square meters in the third phase of the Life Science Park.

As the third phase of the "Beijing Darts International Innovation Platform", the "Life Valley Dart Innovation Complex" will gather innovative resources and empower innovation and entrepreneurial enterprises. The main line provides high -quality, modular, and flexible series of space products and integrated professional services for high -quality start -up enterprises, high -growth (accelerated) enterprises, and well -known domestic and foreign enterprises innovation projects.

It is understood that in 2021, Changping District made full use of the industrial advantages in the field of life science and pharmaceutical health. In the science and technology innovation area of ​​China (Beijing) Pilot Trade Zone, the first support for professional incubation accelerators. Beijing Dartgive International Innovation Platform ". The project is promoted in three phases. The first and second phases are relying on Building B of the Innovation Building of the Life Park. The total area of ​​about 8,600 square meters will not only provide world -class laboratories and fine operation management, but also provide professional solutions for the development of enterprise development. Plan and on -site R & D technical support, focusing on services and satisfying the common needs of research and development of innovative enterprises in the fields of drug development, gene editing, vaccine research and development, etc., truly realized the innovative project "bags".

At present, the first -phase settlement rate has reached 80%, and the total financing has reached 800 million yuan, which has accurately helping the development of the biopharmaceutical industry in Chang. In addition, on this open platform, many seeds have accelerated the growth: Fan Enshi Company, an emerging leader of innovation research and clinical development in the field of tumor field, PT217, which is used to treat small cell lung cancer, obtained FDA orphan drugs. In the field of new drug development, especially macromolecular drugs, Hua Shenzhi Pharmaceuticals innovatively developed high -efficiency machine learning algorithms and data acquisition technology, and reconstructed drug development processes, which greatly improved the speed and efficiency of new drug research and development.

Photo/Shang Ying

- END -